SCHEMBL4580924

SCHEMBL4580924

Nc1ccc(-c2ccc(Cl)c(Cl)c2)cc1NC(=O)c1ccc(O)cc1

nearest known ligand 0.58

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 15/20 0.58
HDAC1 Q13547 9/20 0.58
HDAC3 O15379 4/20 0.58
ESR2 Q92731 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15397999 0.86 HDAC1 (0.61) HDAC2HDAC1HDAC3
SCHEMBL4581182 0.83 HDAC2 (0.83) HDAC2HDAC1HDAC3
SCHEMBL4579638 0.83 HDAC2 (0.56) HDAC2HDAC1HDAC3
SCHEMBL4580404 0.82 HDAC2 (0.53) HDAC2HDAC1HDAC3
SCHEMBL15397970 0.82 HDAC2 (0.86) HDAC2HDAC1HDAC3
SCHEMBL4579453 0.81 HDAC2 (0.60) HDAC2HDAC1HDAC3
SCHEMBL4578938 0.79 HDAC1 (0.74) HDAC2HDAC1HDAC3
SCHEMBL12933401 0.79 HDAC2 (0.79) HDAC2HDAC1HDAC3
SCHEMBL4579434 0.77 HDAC1 (0.70) HDAC2HDAC1HDAC3
SCHEMBL4578520 0.77 HDAC2 (0.55) HDAC2HDAC1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8598168-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2013-12-03 US disclosed
US-20080132503-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132503-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC3 HDAC2 5/4885HDAC1 1/4885HDAC3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.